Print Page

Letters to Healthcare Providers
 
Testosterone and other anabolic androgenic steroids (AAS): Risks associated with abuse and dependence (Letter to Healthcare Professionals)
 
 
 
Attachment:
  1. Testosterone and other anabolic androgenic steroids (AAS) Risks associated with abuse and dependence.pdf  
Related Information:
The United States: FDA issues class-wide labeling changes for testosterone produ... Posted 2025-03-01
China: CFDA alerts public to the cardiovascular risk caused by testosterone Posted 2016-12-31
The United States: Testosterone and other anabolic androgenic steroids (AAS): FD... Posted 2016-10-26
Singapore: Testosterone and risk of cardiovascular events Posted 2015-10-08
The United States: Testosterone Products: Drug Safety Communication - FDA cautio... Posted 2015-03-04
European Union: No consistent evidence of an increased risk of heart problems wi... Posted 2014-11-22
European Union: PRAC review does not confirm increase in heart problems with tes... Posted 2014-10-11
Canada: Information Update - Possible cardiovascular problems associated with te... Posted 2014-07-16
Testosterone products - Risk of possible cardiovascular problems (Letter to Heal... Posted 2014-07-16
European Union: Review of testosterone-containing medicines started Posted 2014-04-12
The United States: Testosterone Products: Drug Safety Communication - FDA Invest... Posted 2014-02-04
 
back